The funding will support an early clinical trial for a medication that might help people with a genetic mutation that can lead to extreme weight gain at an early age, the company said. The money came from existing investors, including Amplitude Ventures, FSTQ, Lumira, Investissement Québec and BDC Capital’s Thrive Venture Fund. (The Logic)

Talking point: The potential drug, called CGX-926, is the one farthest along in Congruence’s pipeline—but if it works, it would be a good sign for other drugs it has in the works aimed at diseases that come from protein misfolding, including a form of Parkinson’s. Congruence uses its own computational platform called Revenir to predict drug candidates that can combat these problems; its CEO is serial biotech entrepreneur Clarissa Desjardins; she founded Clementia Pharmaceuticals, which ultimately was bought by Ipsen for $1.3 billion. Congruence previously raised $63 million in a Series A round in 2022.